BMS's ZymoGenetics R&D Facility Earns LEED Silver Certification from US Green Building Council
Bristol-Myers Squibb’s (BMS) ZymoGenetics R&D subsidiary is among an elite group of laboratories around the world that have earned the US Green Building Council’s LEED (Leadership in Energy and Environmental Design) Silver certification for Existing Buildings: Operations and Maintenance.
LEED certification is recognised worldwide as the premier mark of achievement in green building and is awarded at one of four levels — certified, silver, gold and platinum — based on points earned on a LEED scorecard. ZymoGenetics’ Silver certification is a formal acknowledgement of the numerous internal and external environmental considerations that were implemented to make the site a clean, energy-efficient laboratory complex.
“The LEED Silver certification awarded to BMS’s ZymoGenetics R&D subsidiary is a demonstration of our commitment to economic, social and environmental sustainability,” says Susan Voigt, Vice President, Environment, Health, Safety & Sustainability, BMS. “We are proud of the improvements that have been implemented at the facility, which is at the forefront of the research, development and manufacturing of biologic medicines that help patients prevail over serious diseases.”
ZymoGenetics’ 2-year LEED certification project began in July 2012. Since then, the site has met or surpassed LEED standards for air quality and temperature, indoor plumbing and fixture efficiency, energy efficiency, and acoustics. The site has a superior energy performance rating compared to laboratories of similar type and function using the Labs21 Environmental Performance Criteria. LED fixtures and occupancy sensors were installed as part of a lighting upgrade project, and the site has reduced water use by 42% since installing new plumbing fixtures.
“Beyond recognition as a green building, the certification also has pragmatic benefits,” says Mike Fitzpatrick, director, Site & Business Operations, ZymoGenetics. “We increased operational efficiency and reduced our year-over-year usage of electricity by 17%, natural gas by 38% and water by 17%, in addition to reducing our maintenance costs and improving the well-being of our employees, all while reducing our carbon footprint and impact on the environment.”
The site also has policies governing sustainable purchasing, solid waste management and green cleaning, and works with key vendors to ensure their processes, equipment and supplies meet rigorous standards.
Worldwide, only seven laboratories have earned LEED certification for existing building operations and maintenance, and ZymoGenetics is one of only three laboratories that are LEED Silver certified. Six of the LEED certified laboratory existing building operations and maintenance projects are in the US, and two of them are in the State of Washington.
ZymoGenetics focuses on the discovery and early manufacture of therapeutic proteins, or biologics, specifically those with potential applications in Immuno-Oncology (I-O). BMS is at the forefront of this science, which represents a potentially transformational approach to fighting cancer. ZymoGenetics also has core expertise and process development capabilities in the early manufacturing of microbial- and mammalian-based proteins to support toxicology studies and early-stage clinical trials.
Over 50,000 projects are currently participating in the commercial and institutional LEED rating systems, comprising over 9.3 billion square feet or construction space in all 50 states and 135 countries.
“Buildings are a prime example of how human systems integrate with natural systems,” said Rick Fedrizzi, President, CEO & Founding Chair, US Green Building Council. “The ZymoGenetics project efficiently uses our natural resources and makes an immediate, positive impact on our planet, which will tremendously benefit future generations to come.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance